Discovery of penicillin marked a turning point in the history of infection therapy which also led to the emergence of bacterial resistance. It is now 100 years to fight with ever-muted variants of pathogens by developing more and more antibiotics. Since 1987 to todate, no successful class of antibiotic was introduced; this three decade period is known as “the discovery void” period. While, the clinically approved antibiotics are gradually dying in front of bacterial resistance due to which bacterial infections are appearing leading cause of death and disability. Nuclear medicine imaging technique is the strongest modality to diagnose and follow-up of deep-seated and complicated infections. However, the selection of radiolabeled antimicrobial agents plays critical role in gaining sensitivity and specificity of the imaging results. This review comprises of two main sections; first section explains antibiotic targets, and second section explains the imaging efficacy of ^99mTc-labeled antimicrobial agents against bacterial infection along with the emphasis on progress and update of ^99mTc-labeled antibiotics as infection imaging probes. The review, in conclusion, could be an acceleration for radiopharmaceutical chemists for designing and developing ^99mTc-labeled antimicrobial agents to improve infection imaging quality.

中文翻译：

---

用于感染诊断的 99mTc 标记抗生素：机制、作用和进展

青霉素的发现标志着感染治疗史上的一个转折点，这也导致了细菌耐药性的出现。通过开发越来越多的抗生素来对抗病原体变种已经过去了 100 年。自 1987 年至今，没有成功的抗生素类别被引入；这三个十年的时期被称为“发现空白”时期。同时，临床批准的抗生素在细菌耐药性面前逐渐死亡，因此细菌感染似乎是导致死亡和残疾的主要原因。核医学成像技术是诊断和跟踪深部复杂感染的最强方式。然而，放射性标记的抗菌剂的选择在获得成像结果的敏感性和特异性方面起着至关重要的作用。这篇评论包括两个主要部分；第一部分解释抗生素靶点，第二部分解释^99m Tc 标记的抗细菌感染抗菌剂，同时强调^99m Tc 标记的抗生素作为感染成像探针的进展和更新。总之，该审查可能会加速放射性药物化学家设计和开发^99m Tc 标记的抗菌剂以提高感染成像质量。